First Eagle Investment Management LLC Has $14 Million Stock Position in Artivion, Inc. $AORT

First Eagle Investment Management LLC trimmed its holdings in shares of Artivion, Inc. (NYSE:AORT) by 9.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 306,893 shares of the company’s stock after selling 33,500 shares during the period. First Eagle Investment Management LLC’s holdings in Artivion were worth $13,997,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd increased its position in Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Artivion in the 3rd quarter worth about $27,000. USA Financial Formulas increased its position in Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the last quarter. Finally, KBC Group NV acquired a new position in Artivion in the 4th quarter worth about $65,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Price Performance

Shares of NYSE:AORT opened at $23.17 on Wednesday. The business has a 50 day moving average price of $35.70 and a 200 day moving average price of $40.80. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25. The company has a market cap of $1.12 billion, a price-to-earnings ratio of 96.53 and a beta of 1.41. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.15% and a net margin of 2.55%.The firm had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The business’s revenue was up 19.2% on a year-over-year basis. Research analysts predict that Artivion, Inc. will post 0.5 earnings per share for the current year.

Analyst Ratings Changes

AORT has been the topic of several research reports. Needham & Company LLC dropped their target price on Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Citizens Jmp dropped their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Stifel Nicolaus set a $55.00 price target on Artivion in a research note on Thursday, March 5th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $47.83.

Insider Activity

In related news, SVP Marshall S. Stanton sold 2,149 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $81,189.22. Following the completion of the sale, the senior vice president owned 60,097 shares in the company, valued at $2,270,464.66. This represents a 3.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jean F. Holloway sold 8,962 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total value of $340,556.00. Following the sale, the senior vice president owned 185,095 shares of the company’s stock, valued at approximately $7,033,610. The trade was a 4.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 133,043 shares of company stock worth $4,977,158 over the last 90 days. Company insiders own 6.30% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.